Branch Administrator

Oppenheimer analysts say AI in software has moved beyond experimentation, with companies now required to demonstrate measurable returns on investment. AI is becoming a recurring operating expense, with chief financial officers evaluating investments alongside labour costs. The firm says system-of-record vendors and businesses with seat-plus-consumption pricing models are best positioned to benefit. These models offer protection against disruption and the clearest path to AI-driven growth. Oppenheimer's top picks include Microsoft Corporation, citing accelerating platform demand and over $1 billion in AI-related revenue. ServiceNow is highlighted for its exposure to automation and security tailwinds, also exceeding $1 billion in AI revenue. Braze is noted as a system-of-record for customer engagement with durable competitive advantages.

Peapack Private appoints Kevin Bertscha as Senior Vice President, Chief Audit Executive. BEDMINSTER, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) - Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) and Peapack Private Bank & Trust are pleased to announce the appointment of Kevin Bertscha, CPA, as Senior Vice President, Chief Audit Executive. In this role, Bertscha will lead the Bank's internal audit function, overseeing audit strategy, risk assessment, regulatory compliance, internal controls, and governance processes supporting the Company's commitment to strong governance, effective risk management, regulatory compliance, and sustainable growth. Bertscha brings more than 30 years of financial services and internal audit experience, with a distinguished track record of overseeing audit programs for complex financial institutions, broker-dealers, and critical government securities clearing operations. Throughout his career, he has demonstrated expertise in risk management, regulatory compliance, operational resilience, corporate governance, and the implementation of best practices designed to strengthen organizational effectiveness and transparency. Prior to joining Peapack Private, Bertscha served as Managing Director and Deputy Audit Director at Oppenheimer & Co., where he partnered with executive leadership to modernize the firm's annual risk assessment process, enhance audit reporting frameworks, and oversee the execution of high-risk regulatory audits covering broker-dealer operations and financial risk management. Previously, he served as Managing Director and Chief Audit Executive at Industrial and Commercial Bank of China Financial Services, where he was responsible for all internal audit activities, including enterprise risk assessments, audit planning and execution, issue validation, and reporting to senior management, regulatory agencies, and governance committees. He also played a key role in coordinating audit and regulatory activities following a significant cybersecurity incident. Earlier in his career, Bertscha spent more than 25 years with BNY Mellon where he held several senior leadership positions including, Managing Director and Senior Audit Director for the Internal Audit Department, Chief Audit Executive for Global Securities Services, and Global Head of Audit for Pershing, Clearance and Collateral Management, and Treasury Services. He began his financial services career at Bankers Trust Company in New York, serving in both the Global Internal Audit Department and Corporate Trust & Agency division. Bertscha earned a Bachelor of Science degree in Accounting from Rutgers University School of Business. He is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants, The New Jersey Society of Certified Public Accountants, and The Institute of Internal Auditors. He also holds FINRA Series 7, 24, and 63 licenses. Additionally, he serves as an Executive Committee Member of the Prosight Internal Audit Council and holds the Certified Fiduciary and Investment Risk Specialist (CFIRS) designation. He is currently pursuing the Certified Information Systems Auditor (CISA) certification. About the Company Peapack-Gladstone Financial Corporation is a New Jersey bank holding company with total assets of $8.0 billion and assets under management and/or administration of $13.9 billion as of June 30, 2026. Founded in 1921, Peapack Private Bank & Trust is a commercial bank that offers a client-centric approach to banking, providing high-quality products along with customized and innovative wealth management, investment banking, commercial and personal banking solutions. The Bank's wealth management division offers comprehensive financial, tax, fiduciary and investment advice and solutions to individuals, families, privately held businesses, family offices, and not-for-profit organizations, which help them establish, maintain, and expand their legacy. Peapack Private Bank & Trust offers an unparalleled commitment to client service. Visit www.peapackprivate.com for more information.

NYXH stock jumps as ACCCESS trial de-risks sleep apnea bet. TIM BOHEN - UPDATED SEP. 3, 2026, 8:34 AM ET Nyxoah SA stocks have been trading up by 13.25 percent following highly positive clinical progress for its sleep apnea therapy. Key takeaways For NYXH traders. * Breakthrough ACCCESS U.S. trial for Genio in complete concentric collapse sleep apnea hit both 12-month efficacy endpoints with no device-related serious adverse events, backing an FDA PMA supplement filing. * The ACCCESS study delivered a 77.2% responder rate and clean safety profile, targeting a currently untreated obstructive sleep apnea population in the U.S. market. * Oppenheimer slashed its NYXH price target to $4 from $13 but kept an Outperform rating after €7.7M Q2 revenue, including €5.2M from the U.S., and reiterated FY26 guidance. * Cantor Fitzgerald and Piper Sandler both cut NYXH targets but maintained Overweight ratings, pointing to strong commercialization progress and a solid platform for future growth. * Wall Street's mean NYXH target near $6.01 sits well above a roughly $1.41 share price, even after a 15% pop on the ACCCESS news. Live Update At 08:33:36 EDT: On Thursday, September 03, 2026 Nyxoah SA stock [NASDAQ: NYXH] is trending up by 13.25%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. NYXH has been trading like a classic small-cap biotech: tight range, low price, and sudden bouts of momentum. The multi-day chart shows shares mostly stuck between $1.50 and $1.65, with recent closes clustering around $1.51. That tells traders the market was in "show me" mode before the latest ACCCESS catalyst hit. Intraday, NYXH has flashed clear volatility bands. On the 5-minute chart, the stock swung between roughly $1.65 and $1.81, with multiple failed pushes above the $1.78-$1.80 area. That overhead zone now matters. Short-term traders will watch whether NYXH can hold over the mid-$1.70s on volume as confirmation the ACCCESS news is pulling in fresh buying. On the fundamental side, Nyxoah SA remains early-stage. Around $10.02M in trailing revenue and a price-to-sales near 12.9 show traders are paying up for future growth, not current profits. Returns on assets and equity are negative, and pretax margins are deeply in the red, underscoring NYXH as a high-risk development story. With roughly $48.0M in cash and 184 employees, NYXH has some runway, but execution on U.S. growth and regulatory expansion will drive the next leg of the chart. Why traders are watching NYXH after ACCCESS. NYXH finally gave traders what they wanted: hard clinical data in a tough patient group. The U.S. pivotal ACCCESS trial for Nyxoah's Genio system in obstructive sleep apnea patients with complete concentric collapse hit both co-primary efficacy and safety endpoints at 12 months. A 77.2% apnea-hypopnea index responder rate and zero device-related serious adverse events is not just a nice line in a press release. For NYXH, it is the core de-risking event. This matters because the target group is currently underserved in the U.S. Existing hypoglossal nerve stimulation systems generally exclude complete concentric collapse patients. If NYXH secures an FDA PMA supplement and expands the Genio label, it opens a fresh slice of the market rather than just fighting for share in a crowded lane. The market reaction backs that up. NYXH climbed about 15% on the ACCCESS headline, a big move for a stock hanging near $1.50. That kind of spike tells traders the street sees real value in the data, not just another incremental update. At the same time, the analyst backdrop around NYXH is more nuanced. Oppenheimer chopped its price target to $4 from $13, even after highlighting €7.7M in Q2 revenue, with €5.2M coming from the U.S. in only the third full commercial quarter. Cantor Fitzgerald trimmed its NYXH target to $6 from $11 but flagged 89 new U.S. accounts and 55 additional surgeons in Q2, backing a 10%-15% market share goal. Piper Sandler slid its target from $7 to $6 and still calls NYXH Overweight. Put that together and you get a classic setup: NYXH is a beaten-down growth name with upgraded clinical proof, accelerating U.S. commercialization, and a Street consensus target near $6.01 versus a roughly $1.41 stock. That gap will attract momentum and swing traders, but only if the tape confirms with sustained volume and higher lows. Conclusion. For active traders, NYXH is now a textbook catalyst play layered on top of a long-term growth story. The ACCCESS data gives Nyxoah SA something most small med-tech names never get: strong efficacy, clean safety, and a clear regulatory path toward a label expansion in a currently untreated U.S. population. That is why NYXH ripped on the headline and why the story does not end with one green day. The fundamentals still look early-stage. NYXH runs negative margins, leans on its cash pile, and trades on future expectations. But the balance sheet shows about $48.0M in cash and a modest liability stack, giving Nyxoah SA time to push Genio deeper into the U.S. market. With 89 new accounts and dozens of added surgeons in Q2, the commercial engine is actually moving, not just promised on a slide deck. Wall Street's stance reflects that tension. Price targets for NYXH are lower across Oppenheimer, Cantor, and Piper, yet all three keep positive ratings and medium-term growth narratives intact. For chart-driven traders, that means respecting both sides: the upside implied by a consensus target roughly four times the recent share price, and the risk that execution or FDA timing slips. As Tim Bohen, lead trainer with StocksToTrade says, "I focus on momentum that's visible right now. Speculation on future moves is outside my playbook." For many short-term traders, that means keying in on the actual price action around these catalysts rather than building elaborate long-range scenarios. As Tim Sykes likes to say, "Patterns repeat, but it's your job to be prepared when they do." NYXH now fits the pattern of a small, speculative biotech with a real catalyst, a sharp re-rating, and plenty of volatility. For traders studying NYXH, that means focusing on the chart, respecting the risk, and treating every move as an educational case study - not a guarantee. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. What happens on Wall Street every Friday afternoon. There's a pattern in small cap stocks that most retail traders have never noticed. A disproportionate number of companies release their biggest news late on Friday afternoon, right as institutional trading desks are already checking out for the weekend. Millionaire trader Tim Sykes has built a specific strategy around that window, when news is breaking but the big money isn't around to react to it until Monday. He calls it the Weekend Gap, and he recorded a free video explaining how he trades it.